Evaluating the effect of a Russian rituximab biosimilar used to treat patients with rheumatoid arthritis on healthcare budgets

Evaluating the effect of a Russian rituximab biosimilar used to treat patients with rheumatoid arthritis on healthcare budgets

Objective: to evaluate the economic impact of therapy with a Russian rituximab (RTM) biosimilar (Acellbia®) in patients with rheumatoid arthritis (RA) on the healthcare budget of the Russian Federation.Material and methods. A review of literature data and economic modeling (budget impact analysis) w...

Full description

Bibliographic Details
Main Author:	R. O. Dreval
Format:	Article
Language:	Russian
Published:	IMA-PRESS LLC 2018-06-01
Series:	Современная ревматология
Subjects:	анализ влияния на бюджет ревматоидный артрит ритуксимаб биоаналог генно-инженерные биологические препараты
Online Access:	https://mrj.ima-press.net/mrj/article/view/826

Similar Items

Safety of using genetic engineering biological agents in rheumatoid arthritis
by: N V Chichasova, et al.
Published: (2010-03-01)

Biological agents for endoprosthetic joint replacement in patients with rheumatoid arthritis
by: Viktoria Nikolaevna Khlaboshina, et al.
Published: (2014-12-01)

A CURRENT VIEW ON THE PROBLEM OF RAPIDLY PROGRESSIVE RHEUMATOID ARTHRITIS
by: Dmitry Evgenyevich Karateyev
Published: (2010-06-01)

Pharmacoeconomic analysis of using biological agents in the treatment of rheumatoid arthritis
by: I. I. Dyakov, et al.
Published: (2014-09-01)

USE OF THE NEW GENETIC ENGINEERING BIOLOGICAL AGENT TOCILIZUMABIN THE TREATMENT OF RHEUMATOID ARTHRITIS
by: E L Nasonov, et al.
Published: (2010-03-01)

Rheumatoid arthritis in real clinical practice: initiation of therapy with biological agents. Results of the «Computer Terminals of Self-Assessment for Patients with Rheumatic Diseases» («TERMINAL-II») project
by: V. N. Amirdzhanova, et al.
Published: (2019-09-01)

The tumor necrosis factor-α inhibitor golimumab in the treatment of rheumatoid arthritis
by: Natalia Vladimirovna Chichasova
Published: (2014-12-01)

Rheumatoid arthritis therapy with genetically engineered biological agents in the Republic of Karelia
by: Irina Mikhailovna Marusenko
Published: (2013-12-01)

Rheumatoid arthritis: problems of treatment at the present stage
by: N. V. Chichasova
Published: (2018-12-01)

The prediction and long-term maintenance of low disease activity during therapy with disease modifying anti-inflammatory drugs for rheumatoid arthritis
by: E.L. Luchikhina
Published: (2014-05-01)

Experience with tofacitinib in the treatment of resistant rheumatoid arthritis
by: A. R. Babaeva, et al.
Published: (2015-06-01)

Abatacept and cardiovascular risk in rheumatoid arthritis: update
by: T. V. Popkova
Published: (2018-01-01)

USE OF RITUXIMAB IN AUTOIMMUNE DISEASES: NEW ASPECTS
by: Dmitry Evgenyevich Karateyev
Published: (2010-09-01)

Possible reasons for the inefficacy of genetically engineered biological agents in rheumatoid arthritis and ways of its prevention
by: Natalia Vladimirovna Chichasova
Published: (2012-06-01)

The problem of laboratory monitoring in therapy with disease-modifying antirheumatic drugs and biological agents in patients with rheumatoid arthritis
by: Yu. V. Muravyev, et al.
Published: (2018-09-01)

Comorbid infections in patients with rheumatoid arthritis
by: B.S. Belov
Published: (2014-05-01)

Combination therapy with leflunomide and genetic engineering biological agents
by: Nataliya Vladimirovna Chichasova, et al.
Published: (2011-06-01)

Difficult-to-treat rheumatoid arthritis in the clinical practice of a rheumatological hospital. First look
by: A. V. Gordeev, et al.
Published: (2022-05-01)

OPTIMIZATION OF PHARMACEUTICAL CARE FOR JUVENILE RHEUMATOID ARTHRITIS AT THE REGIONAL LEVEL
by: A. A. Skripko, et al.
Published: (2018-01-01)

POSSIBILITIES FOR PRESERVING THE RESULTS OF TREATMENT IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AFTER DOSE REDUCTION AND/OR DISCONTINUATION OF BIOLOGICAL AGENTS: A REMARCA STUDY
by: E. L. Luchikhina, et al.
Published: (2016-12-01)

The marked and rapid therapeutic effect of tofacitinib in combination with subcutaneous methotrexate in a rheumatoid arthritis patient with poor prognostic factors who is resistant to standard disease-modifying antirheumatic drugs and biologicals: A clinical case
by: N. V. Demidova, et al.
Published: (2016-03-01)

Experience with long-term use of certolizumab pegol (Cimzia)
by: Karine Arnoldovna Lytkina, et al.
Published: (2013-10-01)

Treatment strategy for rheumatoid arthritis: hot topics
by: D. E. Karateev
Published: (2015-03-01)

Rationales for discontinuation of disease-modifying antirheumatic drugs, biologic agents, and tofacitinib in rheumatoid arthritis
by: Yu. V. Muraviev, et al.
Published: (2018-12-01)

Personalized medicine: Predictors for the efficiency of biological agent therapy for rheumatoid arthritis
by: M. A. Kotovskaya, et al.
Published: (2017-04-01)

Efficacy and Safety of Prolonged Rituximab Treatment in Patients with Systemic Juvenile Idiopathic Arthritis
by: E. I. Alexeeva, et al.
Published: (2013-03-01)

Immunopathogenetic mechanisms of action of ustekinumab, a new drug for the treatment of psoriatic arthritis and psoriasis
by: T. V. Korotaeva, et al.
Published: (2015-06-01)

Predictors of biologic disease modifying antirheumatic drugs withdrawal due to the development of adverse events in patients with rheumatoid arthritis
by: E. N. Koltsova, et al.
Published: (2022-12-01)

Clinical significance of Janus kinase inhibitors in the therapy of rheumatoid arthritis: achievements and prospects
by: V. I. Mazurov, et al.
Published: (2019-10-01)

New etanercept biosimilar — expanding treatment options for immune-mediated inflammatory rheumatic diseases
by: A. E. Karateev, et al.
Published: (2022-12-01)

Evaluation of the health care budget impact of secukinumab treatment in patients with ankylosing spondylitis
by: S. K. Zyryanov, et al.
Published: (2017-04-01)

Experience of guselkumab usage in the treatment of patients with psoriatic arthritis in real clinical practice
by: E. Yu. Loginova, et al.
Published: (2021-10-01)

EFFICACY OF ABATACEPT IN A PATIENT WITH POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS REFRACTORY TO TNF-α
by: Yu. M. Spivakovskii, et al.
Published: (2015-04-01)

Cost-effectiveness study of treatment with biologic disease-modifying antirheumatic drugs in adult patients with active ankylosing spondylitis
by: R. O. Dreval
Published: (2021-02-01)

Infliximab in Russian clinical practice
by: G V Lukina, et al.
Published: (2012-09-01)

MANAGEMENT PROTOCOL FOR PATIENTS WITH JUVENILE ARTHRITIS
by: A. A. Baranov, et al.
Published: (2013-02-01)

Pharmacoeconomic analysis of subdermal tocilizumab in patients with rheumatoid arthritis
by: S. K. Zyryanov, et al.
Published: (2018-05-01)

Experience of the Tocilizumab Application in Systemic Onset Juvenile Arthritis
by: A. V. Krasnopol’skaja, et al.
Published: (2015-11-01)

EFFICACY OF ETANERCEPT IN TREATMENT OF VARIOUS TYPES OF JUVENILE IDIOPATHIC ARTHRITIS
by: O. Yu. Konopel'ko, et al.
Published: (2013-12-01)

Dactylitis in psoriatic arthritis: clinical features, diagnosis, immunopathogenesis, and treatment
by: T. V. Korotaeva, et al.
Published: (2018-04-01)